Compounded Cyclophosphamide and Piroxicam for the Treatment of a Canine Peripheral Nerve Sheath Tumor: A Case Report
Author(s): Pope George, Daleo Charles, Batson SL
Issue: Sep/Oct 2019 - Volume 23, Number 5
View All Articles in Issue
Page(s): 358-364
Download in electronic PDF format for $75
Abstract: For many people, companion animals are family members and partners in life. The diagnosis of a life-threatening illness in a beloved pet can present challenges for the patient and cause stress and grief for its owner. A successful therapeutic outcome often requires the use of commercially manufactured medications that are not produced in the doses or dosage forms tolerated by veterinary patients or are unavailable to, unaffordable for, and/or inaccessible by owners. In those cases, the use of customized compounded preparations is often the best option. In this report, we describe the successful use of 2 compounds (cyclophosphamide and piroxicam) to treat an aggressive peripheral nerve sheath tumor in an older male dog. Formulations for those medications are provided.
Related Keywords: S.L. Batson, dogs, pets, pet ownership, veterinary oncology, pet owners, combination cancer chemotherapy, formulations, peripheral nerve sheath tumor, Schwann cells, schwannoma, neurofibroma, perineuroma, traumatic neuroma, lameness, cyclophosphamide, alkylating agent, hazardous drugs, piroxicam, NSAID, metronomic therapy, immunosuppression, nonsteroidal anti-inflammatory drug, inflammation, case report, therapeutic triad, veterinarian, pharmacist, drug costs, side effects, adverse effects, tumor progression, drug safety, prostaglandin synthesis, thromboxane A2
Related Categories: CANCER AND AIDS, FORMULATIONS, VETERINARY, CASE REPORTS, NEUROLOGY, HAZARDOUS DRUGS